IMBRUVICA® dosing provides options for you and your patients

The most flexibility in formulation choices of any BTKi

As the only BTKi with tablets, capsules and oral suspension, IMBRUVICA® offers different formulation options to meet your patient's administration needs.

IMBRUVICA® is the only BTKi:

  • Available in oral suspension—a formulation option for patients who may have trouble swallowing tablets or capsules
  • With 3 formulation options approved once a day in WM

Dosing to fit your patient’s routine1

Continue IMBRUVICA® treatment until disease progression or unacceptable toxicity.

  • Administer IMBRUVICA® at approximately the same time each day with a glass of water
  • Swallow tablets or capsule whole. Do not open, break, or chew the capsules.
  • Do not cut, crush, or chew the tablets
  • If a dose of IMBRUVICA® is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Do not take extra doses of IMBRUVICA® to make up for the missed dose

For more customized patient management, IMBRUVICA® for WM can be dosed as a single 420-mg tablet or three 140-mg capsules1

Agents administered in combination with IMBRUVICA® require infusion. When administering IMBRUVICA® in combination with rituximab or obinutuzumab, consider administering IMBRUVICA® prior to rituximab or obinutuzumab when given on the same day.

Once-daily dosing is necessary to ensure inhibition of BTK enzymatic activity1

IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1
The Imbruvica Dose Exchange Program logo
  • Patients requiring a dose reduction can exchange their unused tablets for the same number of tablets at the reduced dose strength

  • Your patient can receive their new dose before returning their unused tablets

  • In this safety-based returns program, there will be no additional cost to the patient for any tablets provided at the reduced dose strength

Patients must enroll in the program to apply. To be eligible for participation in the IMBRUVICA® By Your Side Dose Exchange Program, patients must have remaining pills from a current prescription for an FDA-approved indication for IMBRUVICA® and must return their remaining pills.

Abbreviations

BTK=Bruton’s tyrosine kinase, WM=Waldenström's Macroglobulinemia

Reference

1IMBRUVICA® (ibrutinib) Prescribing Information.